Bank of America’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-15
| Closed | -$8 | – | 8802 |
|
|
2025
Q1 | $8 | Buy |
15
+3
| +25% | +$5 | ﹤0.01% | 8223 |
|
|
2024
Q4 | $62 | Buy |
12
+1
| +9% | +$7 | ﹤0.01% | 7833 |
|
|
2024
Q3 | $151 | Hold |
11
| – | – | ﹤0.01% | 7631 |
|
|
2024
Q2 | $170 | Sell |
11
-35,060
| -100% | -$880K | ﹤0.01% | 7593 |
|
|
2024
Q1 | $3.55M | Sell |
35,071
-19,072
| -35% | -$1.21M | ﹤0.01% | 3956 |
|
|
2023
Q4 | $1.28M | Sell |
54,143
-18,502
| -25% | -$311K | ﹤0.01% | 4800 |
|
|
2023
Q3 | $1.47M | Buy |
72,645
+72,457
| +38,541% | +$1.41M | ﹤0.01% | 4525 |
|
|
2023
Q2 | $4.88K | Buy |
188
+43
| +30% | +$1.23K | ﹤0.01% | 7000 |
|
|
2023
Q1 | $3.02K | Sell |
145
-2
| -1% | -$45 | ﹤0.01% | 7163 |
|
|
2022
Q4 | $3K | Sell |
147
-213
| -59% | -$4.01K | ﹤0.01% | 7157 |
|
|
2022
Q3 | $10K | Sell |
360
-40
| -10% | -$1.15K | ﹤0.01% | 7244 |
|
|
2022
Q2 | $11K | Sell |
400
-238
| -37% | -$10.6K | ﹤0.01% | 7367 |
|
|
2022
Q1 | $51K | Sell |
638
-261
| -29% | -$32.2K | ﹤0.01% | 7170 |
|
|
2021
Q4 | $183K | Buy |
899
+387
| +76% | +$96.6K | ﹤0.01% | 6548 |
|
|
2021
Q3 | $165K | Buy |
512
+74
| +17% | +$21.6K | ﹤0.01% | 6432 |
|
|
2021
Q2 | $114K | Buy |
438
+429
| +4,767% | +$131K | ﹤0.01% | 6449 |
|
|
2021
Q1 | $3K | Buy |
+9
| New | +$3.63K | ﹤0.01% | 7207 |
|
|
2020
Q4 | – | Sell |
-30
| Closed | -$7K | – | 7425 |
|
|
2020
Q3 | $7K | Buy |
+30
| New | +$6.1K | ﹤0.01% | 6538 |
|
Other funds holding VINC
Bank of America's VINC Position: Q2 2025 in Review
Bank of America sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2025, closing a stake of 15 shares — an estimated $8 sold.
Bank of America first reported a position in VINC in Q3 2020 and held it in 18 quarters. The position peaked at $3.55M in Q1 2024. 1 fund tracked by Wall St. Rank holds VINC as of Q2 2025.
- Bank of America reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- Bank of America sold 15 Vincerx Pharma, Inc. Common Stock shares in Q2 2025, an estimated $8.
- Bank of America first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
- Bank of America's Vincerx Pharma, Inc. Common Stock position peaked at $3.55M in Q1 2024.
- 1 fund tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2025.
Based on Bank of America's 13F filing for Q2 2025, filed 14 Aug 2025.